QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

Stopped The study was terminated before any dose escalation occurred in order to pursue other studies designed to more extensively evaluate the combination of ETBX-011 and N-803 along with other immunotherapy agents.

Conditions

• Thyroid Cancer
• Colon Cancer
• Ovarian Cancer
• Breast Cancer
• Lung Cancer
• Pancreatic Cancer

Interventions

• BIOLOGICAL: ETBX-011
• BIOLOGICAL: ALT-803

Sponsor

NantCell, Inc.